𝛼SK or Searchbullish
Artrya (ASX:AYA): 2Q26 results inline; $76.5 million in cash; SAPPHIRE progressing
SUMMARY
- Artrya reported its quarterly results, which were broadly in line with expectations.
- Including the $30 million term deposit, AYA has $76.5 million in cash with a further $5.6 million expected in March from the R&D tax rebate.
- The biggest news from the release is the delay of Salix Coronary Flow with AYA continuing its “calibration and refinement”.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Artrya (ASX:AYA): 2Q26 results inline; $76.5 million in cash; SAPPHIRE progressing08 Feb 2026
x